NCOA6

NCOA6 Full Name

nuclear receptor coactivator 6

NCOA6 Introduction

NCOA6, also known as NRC (nuclear receptor coactivator), RAP250 (nuclear receptor coactivator RAP250), or AIB3 (amplified in breast cancer 3), is a 250-kDa protein that functions as a key transcriptional coactivator for multiple nuclear receptors and other transcription factors. Unlike receptor-specific coactivators, NCOA6 serves as an integrating platform, coordinating the assembly of large coactivator complexes at enhancer and promoter regions. It lacks intrinsic enzymatic activity but recruits essential histone acetyltransferases (HATs) such as p300/CBP and methyltransferases (e.g., CARM1), thereby facilitating chromatin remodeling and transcriptional activation. NCOA6 is ubiquitously expressed in human tissues, with highest levels in the testis, ovary, adrenal gland, and certain regions of the brain. The gene is located on chromosome 20q11.22 and spans more than 100 kb, containing 15 exons. Alternative splicing generates several isoforms, though the full-length protein is the most functionally characterized.

Figure 1.The structure of NCOA6 protein.

Coactivator Function and Coregulator Network
NCOA6 belongs to the p160 family of coactivators (SRC/p160 family – SRC-1, SRC-2, SRC-3) but is structurally distinct, with a unique ability to simultaneously interact with multiple classes of transcription factors. It directly binds to liganded nuclear receptors including estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), glucocorticoid receptor (GR), thyroid hormone receptor (TR), retinoic acid receptors (RAR/RXR), and peroxisome proliferator-activated receptors (PPARs). In addition, NCOA6 coactivates other transcription factors such as GATA1/2/3, NF-κB, and STAT6, implicating it in diverse signaling pathways. The LXXLL motifs (where L=leucine, X=any amino acid) within NCOA6 are critical for agonist-dependent receptor interaction. Upon ligand binding, nuclear receptors undergo conformational changes that expose a hydrophobic groove capable of accommodating these LXXLL helices. NCOA6 then recruits secondary coactivators like p300/CBP, which acetylates histones and transcription factors, creating a more permissive chromatin environment. The coactivation activity of NCOA6 is itself regulated by post-translational modifications including phosphorylation (by MAPK, CDK2, and PKA), acetylation, and ubiquitin-mediated degradation, providing dynamic control of transcription.

Clinical Significance of NCOA6 Dysregulation
Dysregulation of NCOA6 expression or function is closely associated with a variety of human diseases, including cancer, metabolic disorders, and developmental abnormalities. Aberrant overexpression of NCOA6 has been observed in multiple types of cancer, including breast cancer, lung cancer, liver cancer, and prostate cancer, where it acts as an oncogene to promote tumor cell proliferation, invasion, and metastasis by enhancing the activity of oncogenic transcription factors and nuclear receptors. This overexpression is often associated with poor prognosis and chemoresistance in cancer patients. Conversely, loss-of-function mutations or reduced expression of NCOA6 have been linked to developmental disorders, such as congenital heart defects, neural tube defects, and growth retardation, resulting from impaired transcriptional regulation during embryonic development. Additionally, NCOA6 dysregulation is associated with metabolic disorders, including obesity, diabetes, and non-alcoholic fatty liver disease, due to its role in glucose and lipid metabolism. The estimated frequency of NCOA6 dysregulation varies across cancer types, with high expression detected in approximately 35–55% of breast and liver cancer cases. Furthermore, NCOA6 has been proposed as a potential diagnostic and prognostic biomarker, as well as a therapeutic target for cancer and metabolic disorders.

Alternate Names for NCOA6

NCOA6; nuclear receptor coactivator 6; NRC; AIB3; ASC2; PRIP; TRBP; RAP250; NRC RAP250; PPAR-interacting protein